[Clinical efficiency of the use of monopril, propanolol and heparinum in stationary rehabilitation of patients with myocardial infarction].
Studying of influence of monopril, propranolol and heparin on central hemodynamics, cardiodynamics, volume of defeat and clinical current of myocardial infarction (MI) in the early and late hospital period of disease. 50 patients with an initial front MI with Q wave in the age of from 30 till 70 years are surveyed. By the method of randomization (on a sex, age, extensiveness and localization of necrosis, prescription of stenocardic pains etc.) patients were divided into 2 groups with 25 patients in each. In treatment of 1st group it was used monopril+ propranolol+heparin, of 2nd--propranolol+heparin. With help of EchoCG and DopplerEchoCG studied ESV, EDV, EF, CI, SI, an index of abnormalities of local contractility of left ventricle (ALC), have revealed ventricular extrasystole (VEX) with the help of registration of an electrocardiogram on a magnetic tape during day, and also have established dynamics of BPs, BPd, parameters of PETG--ST, NST, AST, (Rh and features of clinical current of MI during inpatient rehabilitation. Results. Introduction of propranolol and heparin and intake of monopril promoted decrease both BPs, and BPd, however, hypotonia and clinically significant hypotension was not observed. At the same time, reduction of parameters of defeat of a myocardium--(ST, NST, AST, increase of (Rh and also EF, not authentic increase of CI, SI, reduction of ESV, EDV, IALC of LV and impending VEX was marked. Positive dynamics of the specified parameters promoted favorable current of MI, reduction of quantity of patients with postinfarction stenocardia, and also interfered with development of CHF in the late hospital period of MI. During stationary rehabilitation were not registered recurrences and mortality. Dynamics of the above-stated parameters in 2nd group was expressed, but to a lesser degree, than in 1st group. Clinical current of MI in 1st group proceeded more favorably, than in 2nd group.
Agaev
M M
MM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D017328:Fosinopril / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D011433:Propranolol / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D005343:Fibrinolytic Agents; D006493:Heparin; D011433:Propranolol; D017328:Fosinopril